Clinical trial design for invasive aspergillosis: time to cast a different mold

References

• Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006; 173: 707–717
   PubMed Web of Science ®Google Scholar
• Anaissie EJ. Trial design for mold-active agents: time to break the mold – aspergillosis in neutropenic adults. Clin Infect Dis 2007; 44: 1298–1306
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Loeffler J, Stevens D. Aspergillosis. Fungal Infections in the Immunocompromised Patient, JR Wingard, E Anaissie. Taylor & Francis Group, New York 2005; 257–294
   Google Scholar
• Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7–14
   PubMed Web of Science ®Google Scholar
• Subira M, Martino R, Rovira M, et al. Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. Ann Hematol 2003; 82: 80–82
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007; 44: 1289–1297
   PubMed Web of Science ®Google Scholar
• Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998; 27: 1406–1412
   PubMed Web of Science ®Google Scholar
• Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359–366
   PubMed Web of Science ®Google Scholar
• Miceli MH, Maertens J, Buve K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 2007; 110: 112–120
   PubMed Web of Science ®Google Scholar
• Maertens JA, Klont R, Masson C, et al. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. Clin Infect Dis 2007; 44: 1329–1336
   PubMed Web of Science ®Google Scholar
• Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis. J Clin Microbiol 1999; 37: 3223–3228
   PubMed Web of Science ®Google Scholar
• Becker MJ, Lugtenburg EJ, Cornelissen JJ, et al. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003; 121: 448–457
   PubMed Web of Science ®Google Scholar
• Chmura Kraemer H, Periyakoil VS, Noda A. Kappa coefficients in medical research. Stat Med 2002; 21: 2109–2129
   PubMed Web of Science ®Google Scholar
• Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008; 46: 1412–1422
   PubMed Web of Science ®Google Scholar
• Woods G, Miceli MH, Grazziutti ML, et al. Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 2007; 110: 830–834
   PubMed Web of Science ®Google Scholar
• Wheat LJ. Antigen detection, serology, and molecular diagnosis of invasive mycoses in the immunocompromised host. Transpl Infect Dis 2006; 8: 128–139
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Shoham S, Petraitiene R, et al. Detection of galactomannan antigenemia in patients receiving piperacillin-tazobactam and correlations between in vitro, in vivo, and clinical properties of the drug-antigen interaction. J Clin Microbiol 2004; 42: 4744–4748
   PubMed Web of Science ®Google Scholar
• El Saleeby CM, Allison KJ, Knapp KM, Walsh TJ, Hayden RT. Discordant rise in galactomannan antigenemia in a patient with resolving aspergillosis, renal failure, and ongoing hemodialysis. J Clin Microbiol 2005; 43: 3560–3563
   PubMed Web of Science ®Google Scholar
• Murashige N, Kami M, Kishi Y, Fujisaki G, Tanosaki R. False-positive results of Aspergillus enzyme-linked immunosorbent assays for a patient with gastrointestinal graft-versus-host disease taking a nutrient containing soybean protein. Clin Infect Dis 2005; 40: 333–334
   PubMed Web of Science ®Google Scholar
• Mennink-Kersten MA, Klont RR, Warris A, Op den Camp HJ, Verweij PE. Bifidobacterium lipoteichoic acid and false ELISA reactivity in Aspergillus antigen detection. Lancet 2004; 363: 325–327
   PubMed Web of Science ®Google Scholar
• Mennink-Kersten MA, Ruegebrink D, Klont RR, et al. Bifidobacterial lipoglycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity. J Clin Microbiol 2005; 43: 3925–3931
   PubMed Web of Science ®Google Scholar
• Dalle F, Charles PE, Blanc K, et al. Cryptococcus neoformans galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus galactomannan. J Clin Microbiol 2005; 43: 2929–2931
   PubMed Web of Science ®Google Scholar
• Ulusakarya A, Chachaty E, Vantelon JM, et al. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. Hematol J 2000; 1: 111–116
   PubMedGoogle Scholar
• Verweij PE, Dompeling EC, Donnelly JP, Schattenberg AV, Meis JF. Serial monitoring of Aspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples. Infection 1997; 25: 86–89
   PubMed Web of Science ®Google Scholar
• Salonen J, Lehtonen OP, Terasjarvi MR, Nikoskelainen J. Aspergillus antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome. Scand J Infect Dis 2000; 32: 485–490
   PubMedGoogle Scholar
• Rovira M, Jimenez M, De La Bellacasa JP, et al. Detection of Aspergillus galactomannan by enzyme immunoabsorbent assay in recipients of allogeneic hematopoietic stem cell transplantation: a prospective study. Transplantation 2004; 77: 1260–1264
   PubMed Web of Science ®Google Scholar
• Moragues MD, Amutio E, Garcia-Ruiz JC, Ponton J. Usefulness of galactomannan detection in the diagnosis and follow-up of hematological patients with invasive aspergillosis. Rev Iberoam Micol 2003; 20: 103–110
   PubMedGoogle Scholar
• Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242–1250
   PubMed Web of Science ®Google Scholar
• Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604–1610
   PubMed Web of Science ®Google Scholar
• Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1– > 3)-beta-d-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004; 42: 2733–2741
   PubMed Web of Science ®Google Scholar
• Walsh, TJ. The low rate of false positive and false negative of GMI in infected animals who underwent autopsy examination revealing both histopathologic and microbiologic evidence of aspergillosis and in uninfected control in experimental studies. In: E Anaissie, 2006. Personal communication. Author: Walsh T. J; Receipient: Anaissie E. J; WashingtonD.C. USA.
   Google Scholar
• Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40: 1762–1769
   PubMed Web of Science ®Google Scholar
• Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641–649
   PubMed Web of Science ®Google Scholar
• Marr KA, Leisenring W. Design issues in studies evaluating diagnostic tests for aspergillosis. Clin Infect Dis 2005; 41: S381–S386
   PubMed Web of Science ®Google Scholar
• Schafer H, Timmesfeld N, Muller HH. An overview of statistical approaches for adaptive designs and design modifications. Biom J 2006; 48: 507–520
   PubMed Web of Science ®Google Scholar
• Gottlieb, S. (10, July, 2006) Remarks on Adaptive Trial Design, 2006. Conference on Adaptive Trial Design, Washington, DC. In: http://www.fda.gov/oc/speeches/2006/trialdesign0710.html, .
   Google Scholar